Kanser g\u00fcn\u00fcm\u00fczde \u00f6nemi giderek artan bir sa\u011fl\u0131k ve ya\u015fam sorunu halini ald\u0131. Erken tan\u0131 ve tedavi y\u00f6ntemleri nedeniyle can kayb\u0131 oranlar\u0131 azalmaya devam etse de t\u00fcm d\u00fcnyada erkek ve kad\u0131nlarda can kay\u0131plar\u0131 nedenleri aras\u0131nda kalp hastal\u0131klar\u0131ndan sonra 2\u2019nci s\u0131rada geldi\u011fini dile getiren T\u0131bbi Onkoloji uzman\u0131 Prof. Dr. Bala Ba\u015fak \u00d6ven, kanserde tedaviden daha \u00f6nemli olan konunun kanserden korunmak oldu\u011funa bir kez daha dikkat \u00e7ekerek \u201cD\u00fcnya Kanser G\u00fcn\u00fc\u201d vesilesiyle \u00f6nemli bilgiler payla\u015ft\u0131.<\/p>\n
D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc verilerine g\u00f6re, kanser vakalar\u0131 her ge\u00e7en y\u0131l d\u00fcnya \u00e7ap\u0131nda art\u0131\u015f g\u00f6stermeye devam etmekte. Bat\u0131 toplumlar\u0131nda her y\u0131l 250 ila 350 ki\u015fiden birinin kanser tan\u0131s\u0131 ald\u0131\u011f\u0131 bilgisini veren Yeditepe \u00dcniversitesi Ko\u015fuyolu Hastanesi T\u0131bbi Onkoloji Prof. Dr. Bala Ba\u015fak \u00d6ven, \u201c60 ya\u015f\u0131n \u00fczerindeki grupta ise kanser s\u0131kl\u0131\u011f\u0131n\u0131n artt\u0131\u011f\u0131 ve her 300 ki\u015fide 4-5 civar\u0131na y\u00fckseldi\u011fi g\u00f6r\u00fcl\u00fcyor. \u00dclkemizde kesin istatistikler bulunmamakla birlikte insidans\u0131n bunun yar\u0131s\u0131 kadar oldu\u011fu tahmin ediliyor\u201d diye konu\u015ftu.<\/p>\n
BU KANSERLER T\u00dcM KANSERLER\u0130N Y\u00dcZDE 50\u2019DEN FAZLASINI OLU\u015eTURUYOR<\/strong><\/p>\n T\u00fcrkiye\u2019de en s\u0131k g\u00f6r\u00fclen ilk 5 kanser t\u00fcr\u00fc akci\u011fer kanseri, meme kanseri, ba\u011f\u0131rsak kanseri, prostat kanseri ve tiroid kanseri oldu\u011funu ve bu 5 kanser t\u00fcr\u00fcn\u00fcn, t\u00fcm kanserlerin y\u00fczde 50’den fazlas\u0131n\u0131 olu\u015fturdu\u011funu i\u015faret eden Prof. Dr. Bala Ba\u015fak \u00d6ven, s\u00f6zlerine \u015f\u00f6yle devam etti: <\/p>\n \u201cErkeklerde ilk be\u015f s\u0131rada akci\u011fer, prostat, ba\u011f\u0131rsak, mesane kanseri ve mide kanseri yer al\u0131yor. Kad\u0131nlarda ise meme, akci\u011fer, ba\u011f\u0131rsak ve rahim kanseri olarak s\u0131ralan\u0131yor. Meme kanseri kad\u0131nlarda en s\u0131k g\u00f6r\u00fclen kanser t\u00fcr\u00fc olup her 8 kad\u0131ndan 1\u2019i hayat\u0131 boyunca meme kanserine yakalanabiliyor. Yine sigara i\u00e7iminin kad\u0131nlar aras\u0131nda da artmas\u0131yla beraber her iki cinsiyet i\u00e7in de akci\u011fer kanseri en s\u0131k can kayb\u0131na neden olan kanser t\u00fcr\u00fc olarak g\u00f6r\u00fcl\u00fcyor. Tarama testlerinin yayg\u0131n kullan\u0131lmas\u0131yla beraber ba\u011f\u0131rsak kanserleri ve meme kanserlerinin s\u0131kl\u0131\u011f\u0131 son y\u0131llarda artm\u0131\u015f g\u00f6r\u00fcn\u00fcyor. Ancak ayn\u0131 zamanda hastalara daha erken evrelerde tan\u0131 konabildi\u011finden tam iyile\u015fme oranlar\u0131 da beraberinde art\u0131yor.\u201d<\/p>\n KANSERDEN KORUNMAK \u0130\u00c7\u0130N UYULMASI GEREKEN 3 KURAL<\/strong><\/p>\n Rakamlar b\u00f6yleyken halen hastalar\u0131n d\u00f6rtte birine yayg\u0131n evrede tan\u0131 konulabildi\u011fine dikkat \u00e7eken Prof. Dr. Bala Ba\u015fak \u00d6ven, zaman\u0131nda ve do\u011fru tan\u0131n\u0131n \u00f6neminin her ge\u00e7en g\u00fcn daha da \u00f6nem kazand\u0131\u011f\u0131n\u0131 s\u00f6yledi. \u201cKanserde belki tedaviden daha \u00f6nemli olan konu kanserden korunmakt\u0131r\u201d diyen Prof. Dr. \u00d6ven, \u201cKanserden korunmak i\u00e7in uyulmas\u0131 gereken \u00fc\u00e7 kural\u0131n ba\u015f\u0131nda; kanser yap\u0131c\u0131 maddelerden uzak durmak, d\u00fczenli egzersiz yapmak, sa\u011fl\u0131kl\u0131 beslenme ile kanser s\u0131kl\u0131\u011f\u0131n\u0131 rahat\u00e7a yar\u0131ya indirebilir\u201d ifadelerini kulland\u0131.<\/p>\n \u201cKANSER ARTIM \u00d6NLENEB\u0130L\u0130R VE TEDAV\u0130 ED\u0130LEB\u0130L\u0130R B\u0130R HASTALIK\u201d<\/strong><\/p>\n Tan\u0131, tarama ara\u00e7lar\u0131 ve tedavide ya\u015fanan geli\u015fmelerle kanserin g\u00fcn\u00fcm\u00fczde art\u0131k \u00f6nlenebilir ve tedavi edilebilir bir hastal\u0131k oldu\u011funu s\u00f6yleyen Prof. Dr. Bala Ba\u015fak \u00d6ven, \u015fu bilgileri verdi:<\/p>\n \u201c\u00d6zellikle son y\u0131llarda kanser tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an yeni hedefe y\u00f6nelik tedaviler ve immunoterapilerle hastalar\u0131m\u0131z\u0131n ya\u015fam kalitesi bozulmadan uzun ya\u015fam s\u00fcreleri elde edilebiliyor. \u0130mmunoterapiye yan\u0131t veren hastalarda daha y\u00fcksek oranlarda sa\u011f kal\u0131m elde edilebiliyor.\u201d<\/p>\n Prof. Dr. \u00d6ven, \u00f6zellikle akci\u011fer kanserli hastalarda her 3 hastadan birinde 5 y\u0131l\u0131n \u00fczerinde sa\u011f kal\u0131mlar g\u00f6r\u00fcld\u00fc\u011f\u00fcne de dikkat \u00e7ekti. <\/p>\n","protected":false},"excerpt":{"rendered":" D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc’n\u00fcn bir alt kurulu\u015fu olan Uluslararas\u0131 Kanser Ara\u015ft\u0131rma Ajans\u0131 (IARC), k\u00fcresel kanser y\u00fck\u00fcne ili\u015fkin en son tahminleri, d\u00fcnya kanser istatistiklerini en son 2020\u2019de kamuoyu ile payla\u015ft\u0131. \u0130statistiklere g\u00f6re T\u00fcrkiye\u2019de 233 bin ki\u015fiye kanser tan\u0131s\u0131 kondu\u011funu, bunun da 132 bin erkek (y\u00fczde 56,6) 101 bininin kad\u0131n (y\u00fczde 43,4) oldu\u011funu s\u00f6yleyen T\u0131bbi Onkoloji Uzaman\u0131 Prof. Dr. Bala Ba\u015fak \u00d6ven, \u201cBu verilere g\u00f6re, her g\u00fcn 360 erkek, 275 kad\u0131n kanser tan\u0131s\u0131 alarak m\u00fccadeleye ba\u015fl\u0131yor\u201d dedi.<\/p>\n","protected":false},"author":6,"featured_media":9753,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53],"tags":[2285,527,2286,87],"class_list":["post-9751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-dunya-saglik-orgutu","tag-kanser","tag-prof-dr-bala-basak-oven","tag-saglik"],"_links":{"self":[{"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/posts\/9751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/comments?post=9751"}],"version-history":[{"count":1,"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/posts\/9751\/revisions"}],"predecessor-version":[{"id":9754,"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/posts\/9751\/revisions\/9754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/media\/9753"}],"wp:attachment":[{"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/media?parent=9751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/categories?post=9751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ihm.tr\/tr-int\/wp-json\/wp\/v2\/tags?post=9751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}